share_log

HC Wainwright & Co. Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $1.5

HC Wainwright & Co. Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $1.5

HC Wainwright&Co.以買入評級啟動對Akari治療公司的報道,宣佈目標價為1.5美元
Benzinga Real-time News ·  2022/12/05 06:10

HC Wainwright & Co. analyst Sean Lee initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $1.5.

HC Wainwright&Co.分析師肖恩·李以買入評級啟動對阿卡里治療公司(納斯達克:AKTX)的報道,並宣佈目標價為1.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論